Denali Therapeutics Management
Management criteria checks 4/4
Denali Therapeutics' CEO is Ryan Watts, appointed in Aug 2015, has a tenure of 9.42 years. total yearly compensation is $7.88M, comprised of 8.5% salary and 91.5% bonuses, including company stock and options. directly owns 1.56% of the company’s shares, worth $47.63M. The average tenure of the management team and the board of directors is 6 years and 8.3 years respectively.
Key information
Ryan Watts
Chief executive officer
US$7.9m
Total compensation
| CEO salary percentage | 8.5% |
| CEO tenure | 9.4yrs |
| CEO ownership | 1.6% |
| Management average tenure | 6yrs |
| Board average tenure | 8.3yrs |
Recent management updates
Recent updates
Denali: Despite ALS Primary Endpoint Failure, Possible Path Forward Remains
Jan 09We're Hopeful That Denali Therapeutics (NASDAQ:DNLI) Will Use Its Cash Wisely
Dec 09
Denali Therapeutics: A Promising Biotech With Revolutionary BBB-Crossing Technology
Aug 20Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth
Jul 26Revenues Not Telling The Story For Denali Therapeutics Inc. (NASDAQ:DNLI) After Shares Rise 25%
May 23Denali Therapeutics: MPS Treatment Program Continues With End Of 2024 Data
May 13An Intrinsic Calculation For Denali Therapeutics Inc. (NASDAQ:DNLI) Suggests It's 44% Undervalued
Apr 17Denali Therapeutics Inc.'s (NASDAQ:DNLI) Price Is Right But Growth Is Lacking After Shares Rocket 25%
Mar 21Denali: Leveraging Transport Vehicle Technology For Neurological Gains
Mar 07Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth
Feb 21Improved Revenues Required Before Denali Therapeutics Inc. (NASDAQ:DNLI) Shares Find Their Feet
Jan 26We're Not Very Worried About Denali Therapeutics' (NASDAQ:DNLI) Cash Burn Rate
Nov 20Investor Optimism Abounds Denali Therapeutics Inc. (NASDAQ:DNLI) But Growth Is Lacking
Oct 09Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth
Aug 22Denali Therapeutics Inc.'s (NASDAQ:DNLI) Intrinsic Value Is Potentially 69% Above Its Share Price
May 02Analysts Are More Bearish On Denali Therapeutics Inc. (NASDAQ:DNLI) Than They Used To Be
Mar 04Here's Why We're Not Too Worried About Denali Therapeutics' (NASDAQ:DNLI) Cash Burn Situation
Feb 06These Analysts Think Denali Therapeutics Inc.'s (NASDAQ:DNLI) Sales Are Under Threat
Nov 09Denali Therapeutics proposes $250M stock offering; shares down 6% post market
Oct 18Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth
Oct 12Biogen, Denali begin dosing in late-stage trial of Parkinson's candidate BIIB122
Oct 10CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$427m |
| Jun 30 2024 | n/a | n/a | -US$420m |
| Mar 31 2024 | n/a | n/a | -US$137m |
| Dec 31 2023 | US$8m | US$670k | -US$145m |
| Sep 30 2023 | n/a | n/a | -US$124m |
| Jun 30 2023 | n/a | n/a | -US$128m |
| Mar 31 2023 | n/a | n/a | -US$371m |
| Dec 31 2022 | US$9m | US$645k | -US$326m |
| Sep 30 2022 | n/a | n/a | -US$303m |
| Jun 30 2022 | n/a | n/a | -US$284m |
| Mar 31 2022 | n/a | n/a | -US$286m |
| Dec 31 2021 | US$13m | US$610k | -US$291m |
| Sep 30 2021 | n/a | n/a | US$30m |
| Jun 30 2021 | n/a | n/a | US$56m |
| Mar 31 2021 | n/a | n/a | US$58m |
| Dec 31 2020 | US$9m | US$589k | US$71m |
| Sep 30 2020 | n/a | n/a | -US$228m |
| Jun 30 2020 | n/a | n/a | -US$216m |
| Mar 31 2020 | n/a | n/a | -US$215m |
| Dec 31 2019 | US$5m | US$567k | -US$198m |
| Sep 30 2019 | n/a | n/a | -US$66m |
| Jun 30 2019 | n/a | n/a | -US$55m |
| Mar 31 2019 | n/a | n/a | -US$52m |
| Dec 31 2018 | US$6m | US$545k | -US$36m |
Compensation vs Market: Ryan's total compensation ($USD7.88M) is about average for companies of similar size in the US market ($USD6.65M).
Compensation vs Earnings: Ryan's compensation has been consistent with company performance over the past year.
CEO
Ryan Watts (48 yo)
9.4yrs
Tenure
US$7,879,267
Compensation
Dr. Ryan J. Watts, Ph D., serves as Director at PEEL Therapeutics, Inc. since February 2023. He is the Co-Founder of Denali Therapeutics Inc. and has been its President and Chief Executive Officer since Au...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 9.4yrs | US$7.88m | 1.56% $ 47.6m | |
| Co-Founder | 9.8yrs | US$4.17m | 0.42% $ 13.0m | |
| Co-Founder & Independent Director | no data | US$431.93k | 1.47% $ 44.9m | |
| Chief Medical Officer & Head of Development | 9.6yrs | US$4.17m | 0.16% $ 4.8m | |
| Senior Vice President of Corporate Finance | no data | no data | no data | |
| Chief Technical and Manufacturing Officer | 6.4yrs | no data | no data | |
| Chief Scientific Officer | 4.5yrs | no data | no data | |
| Vice President of Investor Relations | 5yrs | no data | no data | |
| General Counsel | 6yrs | no data | no data | |
| Vice President of Corporate Development | 2yrs | no data | no data | |
| Chief People Officer | no data | no data | no data | |
| Chief Commercial Officer | 3.3yrs | no data | no data |
6.0yrs
Average Tenure
51yo
Average Age
Experienced Management: DNLI's management team is seasoned and experienced (6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 9.8yrs | US$7.88m | 1.56% $ 47.6m | |
| Co-Founder & Independent Director | 9.8yrs | US$431.93k | 1.47% $ 44.9m | |
| Independent Chairperson | 9.8yrs | US$459.43k | 0.071% $ 2.2m | |
| Independent Director | 9.8yrs | US$444.43k | 0.24% $ 7.2m | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 9.8yrs | US$439.43k | 0.042% $ 1.3m | |
| Member of Scientific Advisory Board | 4.2yrs | no data | no data | |
| Independent Director | 6.8yrs | US$439.43k | 0.011% $ 330.0k | |
| Independent Director | 6.2yrs | US$429.43k | 0.0098% $ 299.1k | |
| Director | 2.7yrs | US$419.43k | 0.55% $ 16.9m | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | 4yrs | no data | no data |
8.3yrs
Average Tenure
64yo
Average Age
Experienced Board: DNLI's board of directors are considered experienced (8.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/10 01:36 |
| End of Day Share Price | 2025/01/08 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Denali Therapeutics Inc. is covered by 23 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Joel Beatty | Baird |
| Caroline Palomeque | Berenberg |
| Tazeen Ahmad | BofA Global Research |